MIRA INFORM REPORT

 

 

Report Date :

29.12.2008

 

IDENTIFICATION DETAILS

 

Name :

RA CHEM PHARMA LIMITED

 

 

Formerly Known As :

IGOR DYESPEC PRIVATE LIMITED

 

 

Registered Office :

6-3-1239/2, “AMAR”, 4th Floor, Raj Bhavan Road, Somajiguda, Hyderabad – 500082, Andhra Pradesh.

 

 

Country :

India

 

 

Financials (as on) :

31.03.2007

 

 

Date of Incorporation :

08.01.1996

 

 

Com. Reg. No.:

01- 22816

 

 

CIN No.:

[Company Identification No.]

L24110AP1996PLC022816

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

HYDI00508E

 

 

PAN No.:

[Permanent Account No.]

AAACI6448M

 

 

Legal Form :

Closely Held Public Limited Liability Company.

 

 

Line of Business :

Manufacturer of Bulk Drugs and Intermediates

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 652000

 

 

Status :

Good

 

 

Payment Behaviour :

Usually Correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well established company having satisfactory track records. Trade relations are fair. Financials position is satisfactory. Payments are usually correct and as per commitments.

 

The company can be considered normal for business dealings at usual trade terms and conditions.

 

 

LOCATIONS

 

Registered Office :

6-3-1239/2, “AMAR”, 4th Floor, Raj Bhavan Road, Somajiguda, Hyderabad – 500082, Andhra Pradesh, India.

Tel. No.:

91-40-66668283 / 66668485

Fax No.:

91-40-66138677

E-Mail :

info@rachempharma.com

raj@rachempharma.com

 

 

Factory 1 :

R.S.No. 50/1, Mukteswarapuram Jaggaiahpeta Mandal, Krishna District, Andhra Pradesh, India.

 

 

DIRECTORS

 

Name :

Mr. J. Rajender Rao

Designation :

Managing Director

Address :

Road No. 12, Banjara Hills, Hyderabad – 500034, India.

Date of Birth/Age :

20.11.1967

Date of Appointment :

14.03.2003

 

 

Name :

Mr. R. Sirish Kumar

Designation :

Director

Address :

253/3RT, Vijaya Nagar Colony, Hyderabad – 500057, India.

Date of Birth/Age :

08.07.1965

Date of Appointment :

14.03.2003

 

 

Name :

Dr. B. Srinivasa Reddy

Designation :

Director

Address :

310, Srinilaya Apartment, Yellareddyguda, Hyderabad, India.

Date of Birth/Age :

01.07.1966

Date of Appointment :

14.03.2003

 

 

Name :

Mr. Ravi Yerra

Designation :

Director

Address :

Flat #02, Jubilee Heavens, 104, Womens Co-operative Housing Society, Jubilee Hills, Hyderabad – 500033, India.

Date of Birth/Age :

05.03.1961

Date of Appointment :

01.10.2005

 

 

Name :

Mr. Pritam Singh

Designation :

Director

Address :

7, Rukminidevi Colony, Phase-II, Opp. AOC Centre, Maredpally, Secunderabad, India.

Date of Appointment :

01.10.2005

 

 

Name :

Mr. Ashok Adityan

Designation :

Director

Address :

50/1, Kanta Basti, Off Malhotra Marg, Tirumalgherry, Hyderabad – 500061, Andhra Pradesh, India.

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

AS ON 30.09.2006

 

Names of Shareholders

 

No. of Shares

 

 

 

Laxmi Ra Holding and Investments Private Limited

 

3399996

Ontario Inc

 

1040000

Mr. Joseph Herman

 

360000

Mr. Rajender Rao

 

1

Ms. Renuka R. Rao

 

1

Ms. Madhavi

 

1

Mr. B. Srinivas Reddy

 

1

Total

 

4800000

 

 

AS ON 31.03.2006

 

Equity Share Breakup

 

Percentage of Holding

Category

 

 

Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others]

 

29.17

Bodies corporate

 

70.83

 

 

 

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Bulk Drugs and Intermediates

 

 

GENERAL INFORMATION

 

No. of Employees :

150

 

 

Bankers :

Ř       3i Infotech Trusteeship Services Limited

3rd to 6th Floor, International Infotech Park, Tower No.5, Vashi Railway Station Complex, Vashi, Navi Mumbai – 400703, Maharashtra, India.

 

Ř       Axis Bank Limited, Begumpet Branch

 

Ř       ICICI Bank Limited, Begumpet Branch

 

 

Facilities :

Secured loans as on 31.03.2007

Particulars

Rs. In Millions

 

 

Term loan

84.078

(secured by equitable mortgage of land and building and by way of hypothecation of all present and future, movable and immovable assets of the company)

 

 

 

Working capital loan

52.948

(secured against stocks, book debts, movable and immovable properties)

 

 

 

Hire purchase loans

1.861

(secured by hypothecation of motor vehicles)

 

 

 

From members

 

 

 

Foreign currency loans

69.380

(secured by second charge on fixed assets of the company)

 

 

 

Total

208.267

 

Unsecured loans as on 31.03.2007

Particulars

Rs. In Millions

 

 

From companies

3.500

 

 

Others

2.154

 

 

Total

5.654

 

 

 

Banking Relations :

Satisfactory

 

 

Auditors :

 

Name :

Chakradhar and Nandan

Chartered Accountant

Address :

201, Srinath Residential Complex, SD Road, Secunderabad – 500003, Andhra Pradesh, India.

Tel. No.:

91-40-66317174 / 66317598

Email :

Chakradhar_nandan@yahoo.com

 

 

Subsidiaries :

Name :

Indu Pharma Private Limited

CIN No.:

U24239AP2004PTC043904

 

 

Name :

Clinical Research And Biosciences India Private Limited

CIN No.:

U24239AP2006PTC050152

 

 

 

 

 

CAPITAL STRUCTURE

 

AS ON 31.03.2007

 

Authorised Capital :

No. of Shares

Type

Value

Amount

6000000

Equity Shares

Rs. 10/- Each

Rs. 60.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

5487176

Equity Shares

Rs. 10/- Each

Rs. 54.871 Millions

 

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2007

31.03.2006

31.03.2005

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

54.872

48.000

40.000

2] Share Application Money

0.000

10.695

6.410

3] Reserves & Surplus

75.548

33.252

22.120

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

130.420

91.947

68.530

LOAN FUNDS

 

 

 

1] Secured Loans

208.269

163.353

107.355

2] Unsecured Loans

5.654

0.146

0.646

TOTAL BORROWING

213.923

163.499

108.001

DEFERRED TAX LIABILITIES

0.000

0.000

0.849

 

 

 

 

TOTAL

344.343

255.446

177.380

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

189.396

167.123

75.887

Capital work-in-progress

44.191

4.155

61.127

Research and Development

5.935

0.000

0.000

 

 

 

 

INVESTMENT

39.320

0.000

0.000

DEFERREX TAX ASSETS

4.176

2.106

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

76.328

45.723

24.169

 

Sundry Debtors

74.764

76.511

48.699

 

Cash & Bank Balances

4.599

20.930

9.606

 

Other Current Assets

50.603

27.019

0.000

 

Loans & Advances

0.000

0.000

18.920

Total Current Assets

206.294

170.183

101.394

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Current Liabilities

142.822

85.628

61.028

 

Provisions

2.302

2.700

0.000

Total Current Liabilities

145.124

88.328

61.028

Net Current Assets

61.170

81.855

40.366

 

 

 

 

MISCELLANEOUS EXPENSES

0.155

0.207

0.000

 

 

 

 

TOTAL

344.343

255.446

177.380

 

PROFIT & LOSS ACCOUNT

 

PARTICULARS

 

31.03.2007

31.03.2006

31.03.2005

Sales Turnover

264.961

277.057

153.417

Other Income

4.456

7.670

1.658

Total Income

269.417

284.727

155.075

 

 

 

 

Profit/(Loss) Before Tax

5.131

15.235

19.907

Provision for Taxation

(1.100)

1.061

1.298

Profit/(Loss) After Tax

6.231

14.174

18.609

 

 

 

 

Earnings in Foreign Currency :

 

 

 

 

Export Earnings

175.121

134.832

NA

Total Earnings

175.121

134.832

NA

 

 

 

 

Imports :

 

 

 

 

Raw Materials

39.428

32.249

NA

Total Imports

39.428

32.249

NA

 

 

 

 

Expenditures :

 

 

 

 

Raw Material Consumed

140.255

113.585

16.973

 

Purchases made for re-sale

0.000

101.249

86.850

 

Increase/(Decrease) in Finished Goods

(26.802)

0.000

0.000

 

Salaries, Wages, Bonus, etc.

13.964

10.573

7.330

 

Managerial Remuneration

2.040

4.100

2.000

 

Payment to Auditors

0.175

0.150

0.000

 

Interest

13.918

9.510

3.061

 

Insurance Expenses

1.749

2.088

1.233

 

Power & Fuel

11.777

7.662

6.297

 

Depreciation & Amortization

9.441

6.594

3.353

 

Other Expenditure

97.769

13.981

8.071

Total Expenditure

264.286

269.492

135.168

 

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2007

31.03.2006

31.03.2005

PAT / Total Income

(%)

2.31

4.97

12

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

1.90

5.49

12.97

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

1.04

4.43

8.34

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.03

0.16

0.12

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

2.75

2.73

2.46

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.42

1.92

1.66

 

 

LOCAL AGENCY FURTHER INFORMATION

 

FIXED ASSETS

 

Ř       Factory Land

Ř       Plant And Machinery

Ř       Computer

Ř       Furniture And Fixture

Ř       Motor Vehicles

 

This form is for

Creation of charge

Corporate identity number of the company

L24110AP1996PLC022816

Name of the company

RA CHEM PHARMA LIMITED

Address of the registered office or of the principal place of  business in India of the company

6-3-1239/2, “AMAR”, 4th Floor, Raj Bhavan Road, Somajiguda, Hyderabad – 500082, Andhra Pradesh, India.

Type of charge

Movable property (not being pledge)

Others

Particular of charge holder

Name :

3i Infotech Trusteeship Services Limited

Address :

3rd to 6th Floor,International Infotech Park, Tower No.5, Vashi Railway Station Complex, Vashi, Navi Mumbai – 400703, Maharashtra, India.

Email :

Mahalingam.S@3i-itsl.com

CIN :

U72900MH2001PLC132441

Nature of description of the instrument creating or modifying the charge

Deed of hypothecation dated :- 18.06.2008

Date of instrument Creating the charge

18.06.2008

Amount secured by the charge

Rs. 70.000 Millions

Brief particulars of the principal terms an conditions and extent and operation of the charge

Rate of interest

Cash credit -13.25% P.A

Export packing credit -13.25% p.a

Foreign bill purchased (FBD)-13.25% p.a

 

Terms of repayment

As per credit arrangement letter

 

Margin

As per credit arrangement letter

 

Extent and operation of the charge

Paripassu first charge on entire movable fixed assets.

First charge on paripassu basis on entire assets of present and future.

Short particulars of the property charged

Paripassu first charge on entire movable fixed assets.

First charge on paripassu basis on entire assets of present and future.

 

 

 

 

 

Amalgamation

 

The trading operations within the group were undertaken by a separate company named RA Interchem Private Limited. To add synergy to operations of RA Chempharma Limited and to save  on overheads ans related costs, a proposal to merge RA Interchem Private Limited with the company was moved and pursuant to the sanction of scheme of amalgamation dated 4th August 2006 by the Honable High Court of Andhra Pradesh the merger was approved and the process completed. The company enhanced its authorized capital from Rs. 40.000 millions to 50.000 millions and subsequently to Rs. 60.000 millions. The shareholders of RA Interchem Private Limited were allotted share in the ratio of 2 fully paid up equity shares of Rs. 10/- each in lieu of each fully paid up share of Rs. 10/- ach held by them.

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.47.89

UK Pound

1

Rs.70.84

Euro

1

Rs.67.37

 

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

6

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

6

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

6

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

54

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions